Search company, investor...

ARYX Therapeutics

aryx.com

Founded Year

1997

Stage

PIPE | IPO

Total Raised

$110.4M

About ARYX Therapeutics

ARYx Therapeutics is a privately-held pharmaceutical research and development company focused on addressing safety concerns in well-established and commercially successful existing therapies through application of its proprietary ARYx RetroMetabolic (ARM) drug design. ARYx improves today's drugs, making proven therapies safer. ARYx currently has three products in clinical trials. For more information, please see the company's web site at www.aryx.com.

Headquarters Location

6300 Dumbarton Circle

Fremont, California, 94555,

United States

510-585-2200

Missing: ARYX Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: ARYX Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing ARYX Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

ARYX Therapeutics is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

ARYX Therapeutics Patents

ARYX Therapeutics has filed 3 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/21/2007

5/31/2011

Calcium channel blockers, Piperidines, Amines, Fluoroarenes, Designer drugs

Grant

Application Date

12/21/2007

Grant Date

5/31/2011

Title

Related Topics

Calcium channel blockers, Piperidines, Amines, Fluoroarenes, Designer drugs

Status

Grant

ARYX Therapeutics Frequently Asked Questions (FAQ)

  • When was ARYX Therapeutics founded?

    ARYX Therapeutics was founded in 1997.

  • Where is ARYX Therapeutics's headquarters?

    ARYX Therapeutics's headquarters is located at 6300 Dumbarton Circle, Fremont.

  • What is ARYX Therapeutics's latest funding round?

    ARYX Therapeutics's latest funding round is PIPE.

  • How much did ARYX Therapeutics raise?

    ARYX Therapeutics raised a total of $110.4M.

  • Who are the investors of ARYX Therapeutics?

    Investors of ARYX Therapeutics include MPM Capital, OrbiMed Advisors, Montreux Equity Partners, Prudential Private Capital, Pacific Life Insurance and 15 more.

  • Who are ARYX Therapeutics's competitors?

    Competitors of ARYX Therapeutics include Adamas Pharmaceuticals, Momenta Pharmaceuticals, Intarcia Therapeutics, InClinica, Tolera Therapeutics, Celera Genomics, Nuon Therapeutics, VistaGen, ENTRA Pharmaceuticals, InteKrin Therapeutics and 13 more.

Compare ARYX Therapeutics to Competitors

I
Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

G
GRAPP

Grand River Aseptic Pharmaceutical Packaging is a pharmaceutical contract manufacturing organization (CMO) supporting the rapid development of new biomedicines to the clinical stage in the State of Michigan. Grand River APP is the result of an alliance between Van Andel Institute (www.vai.org) and Grand Valley State University, and is operating as a non-profit, state- and federally funded corporation. Grand River APP's first aims to assure that therapeutics are properly distributed into dosage forms for all-important Phase I and Phase II human clinical trials. This process, Fill/Finish and Lyophilization, will be offered broadly to academic, nonprofit, and for-profit organizations in Michigan and across North America for liquid-based drug candidates that require vialing in an FDA-regulated aseptic clean room environment. Typical products envisioned for Grand River APP services include small molecule drugs, peptides, monoclonal antibodies, therapeutic proteins and nano-medicines. As a consequence, however, Grand River APP cannot process cytotoxic/genotoxic or virally-based candidates (e.g. viral vaccines).

C
Chakshu Research

Led by a team with vast experience in pharmaceuticals, ophthalmology and start-ups, Chakshu Research is committed to develop pharmaceutical treatments for degenerative ocular diseases. The company are developing a self-administered eyedrop to reduce and repair oxidative damage which has been implicated in blinding degenerative diseases. While the company's drug platform is being tested on the company's lead indication, cataract; the company are also in clinical trials for glaucoma and asteroid hyalosis.

P
Paragon Pharmacies

Paragon Pharmacies Ltd. Incorporated in 2002, with a view to becoming a player in the Canadian pharmacy industry, Paragon is built on a foundation of successful pharmacy operations and is purchasing independent pharmacies at attractive valuations in western Canada. Given the phenomenal valuation growth experienced by national drug chains, Paragon is developing a presence of community-oriented pharmacies across the country with an initial focus on the western Canadian market. www.paragonpharmacies.com

C
Charleston Laboratories

Charleston Laboratories, Inc is a specialty pharmaceutical company focused on the research and development of pain products that prevent or significantly reduce nausea and vomiting, the two most burdensome side effects related to opioid analgesics and other pain associated disease states.

A
Appian International Research

Appian aims to provide consulting and operational support in pharmaceutical product development. The company grew out of the contract pharmaceutical research industry. Dr. Grier Harris, Appian's President, has worked in clinical trials since 1986 in most areas within the industry - from basic medical research to large scale international clinical trials.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.